

# Hyperinsulinemic Hypoglycemia in Beckwith-Wiedemann, Sotos, and Kabuki Syndromes: A Nationwide Survey in Japan

戸田, 尚子

<https://hdl.handle.net/2324/4495982>

---

出版情報：九州大学, 2021, 博士（医学）, 論文博士  
バージョン：  
権利関係：やむを得ない事由により本文ファイル非公開（2）

1 This is the peer reviewed version of the following article: Naoko Toda et. al.  
2 Hyperinsulinemic Hypoglycemia in Beckwith-Wiedemann, Sotos, and Kabuki  
3 Syndromes: A Nationwide Survey in Japan. American journal of medical genetics  
4 173(2) 360-367 (2017), which has been published in final form at  
5 <https://doi.org/10.1002/ajmg.a.38011>. This article may be used for non-commercial  
6 purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived  
7 Versions.

8

9

10

11

12

13

14

15

16

17

18

1 CATEGORY OF THE MANUSCRIPT

2 Original Article

3 TITLE

4 Hyperinsulinemic hypoglycemia in Beckwith-Wiedemann, Sotos and Kabuki

5 syndromes: A nationwide survey in Japan

6 RUNNING HEAD

7 HH in BWS, Sotos and Kabuki

8 AUTHOR

9 Naoko Toda<sup>1\*</sup>, M.D., Kenji Ihara<sup>1,2</sup>, M.D., Ph.D., Kanako Kojima-Ishii<sup>1</sup>, M.D., Ph.D.,  
10 Masayuki Ochiai<sup>1</sup>, M.D., Ph.D., Kazuhiro Ohkubo<sup>1</sup>, M.D., Yutaka Kawamoto<sup>3</sup>, M.D.,  
11 Yoshinori Kohno<sup>4</sup>, M.D., Ph.D., Sakae Kumasaka<sup>5</sup>, M.D., Ph.D., Akihiko Kawase<sup>6</sup>, M.D.,  
12 Yasuhisa Ueno<sup>7</sup>, M.D., Ph.D., Takeshi Futatani<sup>8</sup>, M.D., Ph.D., Tokuo Miyazawa<sup>9</sup>, M.D.,  
13 Ph.D., Yuko Nagaoki<sup>10</sup>, M.D., Setsuko Nakata<sup>11</sup>, M.D., Ph.D., Maiko Misaki<sup>12</sup>, M.D.,  
14 Ph.D., Hiroko Arai<sup>13</sup>, M.D., Ph.D., Masahiko Kawai<sup>14</sup>, M.D., Ph.D., Maki Sato<sup>15</sup>, M.D.,  
15 Ph.D., Yukari Yada<sup>16</sup>, M.D., Ph.D., Nobuhiro Takahashi<sup>17</sup>, M.D., Ph.D., Atsushi  
16 Komatsu<sup>18</sup>, M.D., Ph.D., Kanemasa Maki<sup>19</sup>, M.D., Ph.D., Shinichi Watabe<sup>20</sup>, M.D., Ph.D.,  
17 Yutaka Sumida<sup>21</sup>, M.D., Ph.D., Makoto Kuwashima<sup>22</sup>, M.D., Hiroshi Mizumoto<sup>23</sup>, M.D.,  
18 Kazuo Sato<sup>24</sup>, M.D., Ph.D. and Toshiro Hara<sup>1</sup>, M.D., Ph.D.

1

2 <sup>1</sup>Department of Pediatrics, Graduate School of Medical Science, Kyushu University,  
3 Fukuoka, Japan

4 <sup>2</sup>Department of Pediatrics, Faculty of Medicine, Oita University, Oita, Japan

5 <sup>3</sup>Department of Neonatology, Kawasaki Medical School Hospital, Okayama, Japan

6 <sup>4</sup>Department of Neonatology, Gifu Prefectural General Medical Center, Gifu, Japan

7 <sup>5</sup>Department of Neonatology, Japanese Red Cross Katsushika Maternity Hospital,  
8 Tokyo, Japan

9 <sup>6</sup> Department of Neonatology, Kumamoto City Hospital, Kumamoto, Japan

10 <sup>7</sup>Department of Neonatology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan

11 <sup>8</sup>Department of Pediatrics, Toyama Prefectural Central Hospital, Toyama, Japan.

12 <sup>9</sup>Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan.

13 <sup>10</sup> Department of Pediatrics, St Luke's International Hospital, Tokyo, Japan

14 <sup>11</sup>Department of Pediatrics, Iida Municipal Hospital, Iida, Japan

15 <sup>12</sup>Department of Pediatrics, Hyogo College of Medicine, Nishinomiya, Japan

16 <sup>13</sup>Department of Neonatology, Toho University Omori Medical Center, Tokyo, Japan

17 <sup>14</sup>Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto,  
18 Japan

- 1 <sup>15</sup>Department of Pediatrics, Fukushima Medical University, Fukushima, Japan
- 2 <sup>16</sup>Department of Pediatrics, Jichi Medical University, Shimotsuke, Japan.
- 3 <sup>17</sup>Department of Pediatrics, Tenshi Hospital, Social Medical Corporation BOKOI,  
4 Sapporo, Japan
- 5 <sup>18</sup>Department of Obstetrics and Gynecology, The University of Tokyo Hospital, Tokyo,  
6 Japan
- 7 <sup>19</sup>Department of Pediatrics, Yokkaichi Municipal Hospital, Yokkaichi, Japan
- 8 <sup>20</sup>Department of Neonatal Intensive Care, Kurashiki Central Hospital, Kurashiki, Japan
- 9 <sup>21</sup>Department of Pediatrics, Rinku General Medical Center, Izumisano, Japan
- 10 <sup>22</sup>Department of Pediatrics, Kiryu Kosei General Hospital, Kiryu, Japan
- 11 <sup>23</sup>Department of Pediatrics, Medical Research Institute, Kitano Hospital, Osaka,  
12 Japan
- 13 <sup>24</sup>Department of Pediatrics, National Kyushu Medical Center, Fukuoka, Japan
- 14
- 15 CORRESPONDING AUTHOR
- 16 Naoko Toda, M.D.
- 17 Department of Pediatrics, Graduate School of Medical Science, Kyushu University  
18 3-1-1 Maidashi, Higashi-ku, Fukuoka 814-8582, Japan

1 Phone: +81-92-642-5421

2 Fax: +81-92-642-5435

3 E-mail: [toda.naoko.206@m.kyushu-u.ac.jp](mailto:toda.naoko.206@m.kyushu-u.ac.jp)

4

5

6

7

8

9

1 ABSTRACT

2 Beckwith-Wiedemann syndrome (BWS) is a congenital overgrowth syndrome that is  
3 occasionally associated with hyperinsulinemic hypoglycemia (HH) in the neonatal  
4 period. Sotos syndrome (SS) and Kabuki syndrome (KS) are other malformation  
5 syndromes that may be complicated with HH, however, the detailed clinical  
6 characteristics of HH accompanied with these syndromes remain unclear. We herein  
7 conducted a nationwide questionnaire survey in Japan. We sent a primary questionnaire  
8 concerning the clinical experience for these syndromes to 347 perinatal care institutions.  
9 As a result, 222 departments or hospitals returned the questionnaires and the total  
10 numbers of BWS, SS and KS patients were 113, 88 and 51, respectively. We sent a  
11 secondary questionnaire to 31 institutions where patients with these syndromes  
12 presented with HH during infancy. The secondary questionnaires were returned from the  
13 institutions and the numbers of patients were 16 for BWS, 9 for SS, and 3 for KS,  
14 respectively. Then, we compared the clinical characteristics of infants suffering from  
15 transient HH with and without these dysmorphic syndromes. As a result, BWS, SS and  
16 KS patients showed significantly larger body size, lower Apgar scores, higher insulin  
17 levels at HH and shorter durations of HH than non-dysmorphic infants with transient  
18 HH. We propose that a careful observation for the signs of HH, even if not specific to

1 the syndromes, is important for the diagnosis of patients with BWS, SS and KS in the

2 postnatal period.

3

4 KEY WORD

5 Beckwith-Wiedemann, Sotos, Kabuki, neonatal hyperinsulinemia, hypoglycemia

6



## 1 INTRODUCTION

2 Neonatal hypoglycemia is a critically important complication because it can lead to  
3 neurologic injury. Hyperinsulinism is one of the essential causes of hypoglycemia for  
4 infants and recurrent episodes of hyperinsulinemic hypoglycemia (HH) might render  
5 high risk of permanent brain damage for infants. The severity and pathogenesis of HH  
6 vary widely from life-threatening and refractory against medical treatment to transient  
7 and asymptomatic [Arnoux et al., 2010]. Many genetic causes of HH have been  
8 identified and classified according to the type of functional category: the subunits of K  
9 channels on  $\beta$ -cells, such as ABCC8 and KCNJ11; transcriptional factors for insulin  
10 gene expression, such as HNF1A, HNF4A; and glucose metabolizing enzymes, such as  
11 glucokinase, glutamate dehydrogenase 1 (GLUD1) or uncoupling protein 2 (UCP2)  
12 [Arnoux et al., 2011; Mohamed et al., 2012; Yorifuji, 2014]. Transient HH is  
13 occasionally recognized in infants born from diabetic mothers, and the prolonged HH is  
14 one of responsible causes for hypoglycemia in small for gestational age infants or  
15 asphyxiated newborns. Dysmorphic syndromes are also known to present transient  
16 hyperinsulinism in infancy, especially, Beckwith-Wiedemann syndrome (BWS, OMIM  
17 130650) is well recognized as one of major genetic diseases causing hyperinsulinism  
18 [Munns and Batch, 2001; Weksberg et al., 2010]. Sotos syndrome (SS, OMIM 117550)

1 and Kabuki syndrome (KS, OMIM 147920) are other malformation syndromes  
2 occasionally accompanied with hyperinsulinism, but are less recognized, and detailed  
3 clinical characteristics of HH in SS and KS has remained unclear [Genevieve et al.,  
4 2004; Kapoor et al., 2009; Matsuo et al., 2013; Subbarayan and Hussain, 2014]. We  
5 herein conducted a nationwide questionnaire survey in Japan of 347 institutions with  
6 maternal/perinatal intensive care units to investigate the clinical characteristics of the  
7 patients with dysmorphic syndromes; BWS, SS and KS, who present HH in the neonatal  
8 period. In addition, we compared the clinical characteristics of infants suffering from  
9 transient HH with and without dysmorphic syndromes.

10

## 11 SUBJECTS AND METHODS

12 We sent primary questionnaires to 347 Japanese institutions that have core  
13 maternal/perinatal intensive care unit and asked the neonatologists who cared for the  
14 infants in neonatal intensive care unit (NICU) and then followed them for evaluation their  
15 growth and development regularly at their out-patient clinic. The questionnaire asked for  
16 the clinical experience of patients with either BWS, SS or KS complicated with HH in  
17 infancy during January 2002 to December 2011. We then sent secondary questionnaires  
18 to the institutions that experienced BWS, SS or KS cases with HH, asking for the clinical

1 manifestations including the following items: <data at birth> duration of pregnancy,  
2 weight, length, head circumference, Apgar score, complications during pregnancy;  
3 <characteristic findings at birth> congenital anomalies, facial dysmorphism, chromosome  
4 abnormalities; <symptom of hypoglycemia in the neonatal period> onset of  
5 hypoglycemia, minimum blood glucose level, and <therapy for hypoglycemia> duration  
6 and maximum glucose rate of intravenous glucose infusion (IVG), treatment with  
7 diazoxide or octreotide, estimated duration of hyperinsulinemia. In addition, we  
8 retrospectively collected the clinical data of neonates complicated with transient HH  
9 without any dysmorphic syndromes for a comparison with the clinical characteristics of  
10 those with dysmorphic syndromes.

11 The study was approved by the Institutional Review Board of Kyushu University  
12 Hospital.

### 13 *Statistical analysis*

14 All data were entered and analyzed using the statistical analysis software (SAS) JMP  
15 version 10 (SAS Institute Inc., Cary, NC, USA).

16 The differences between the group of syndromic infants and the group of non-syndromic  
17 infants were analyzed by chi-squared test for the items of maternal complications during  
18 pregnancy, asphyxia and use of diazoxide. The others were evaluated by Mann-Whitney's

1 U test for quantitative variables.

2 Results were regarded statistically significant if P was <0.05.

3

#### 4 RESULTS

5 <The results of the first survey>

6 For the primary questionnaire, 222 departments or hospitals returned the questionnaires  
7 with a response rate of 64%. Approximately half of the institutions, 112, answered the  
8 experience of the care for patients with any of these syndromes; the numbers of patients  
9 were 113 for BWS, 88 for SS and 51 for KS. We sent secondary questionnaires to 31  
10 institutions where patients with any of these syndromes presented with HH during  
11 infancy. The secondary questionnaires were returned from the institutions with the  
12 numbers of 16 for BWS, 9 for SS, and 3 patients for KS, respectively. The clinical data  
13 were collected from medical records of 13 neonates who were admitted to the NICU in  
14 Kyushu University Hospital from 2012-2015 and suffered from transient HH in the  
15 neonatal period without any dysmorphic syndromes. Every parameter was compared  
16 between infants with and without dysmorphic syndromes.

17 < Comparison of clinical and laboratory data between infants with and without  
18 dysmorphic syndrome>

1           Each of the clinical and laboratory data was compared between infants with and  
2 without dysmorphic syndromes.(Table I) As a result, we found that dysmorphic patients  
3 were significantly larger body size (birth weight, birth length, birth head circumference)  
4 than non-dysmorphic patients. And the 1-min Apgar scores of the dysmorphic patients  
5 were significantly lower than those of non-dysmorphic patients. The insulin level at HH  
6 was higher and the duration of HH was shorter in infants with dysmorphic syndromes  
7 than in those without.

8

9 <Clinical characteristics of HH for BWS, SS or KS>

10 1. Data at birth

11 The data of the duration of pregnancy, birth weight, length, and head circumference, the  
12 Apgar scores and complications during pregnancy are presented in Tables II-VI. The  
13 medians (ranges) of the birth weights and weight-SD scores were 3245 g (1294-4272 g)  
14 and 2.8 SD (-0.5- +7.8) for BWS; 3470 g (2330-4756 g) and 1.1 SD (-1.4 - +4.0) for SS;  
15 and 3194 g (2438-3539 g) and 2.0 SD (-1.5- +2.3) for KS, respectively.

16           Asphyxia was complicated in 25% of BWS, 33% of SS and 33% of KS cases  
17 whereas it comprised 0% of non-dysmorphic infants. Maternal complications during  
18 pregnancy, such as pregnancy-induced hypertension (PIH), premature rupture of

1 membranes (PROM), or a non-reassuring fetal status, were found in 69% of BWS, 33%  
2 of SS and 33% of KS cases, respectively (Tables III-V). These complications were  
3 observed at a similar frequency in patients without dysmorphic syndromes (46%; Table  
4 VI). There were no apparent differences among the three syndromes regarding the birth  
5 weight and length or complication of neonatal asphyxia.

## 6 2. Characteristic findings at birth

7 The three major clinical features for BWS, i.e., gigantism, macroglossia and exomphalos,  
8 were observed in most of BWS patients, with the ratios of 68.8%, 81.3%, 43.8%,  
9 respectively. Macrocephaly and large hands and feet were frequently noted in SS patients,  
10 and 70% of SS patients had major cardiovascular or central nervous system anomalies.  
11 All KS cases had specific facial features, such as long palpebral fissures, ectropion of the  
12 lateral third of the lower eyelid, flat nasal tip and large ears.

## 13 3. Cytogenetic data

14 Chromosome abnormalities by G-banding of peripheral lymphocytes were not found in  
15 the analyzed cases, including 9 for BWS, 6 for SS, and 2 for KS. The cytogenetic data  
16 are shown in Tables III-V. One BWS case had chromosome 11p15 paternal UPD. Seven  
17 SS cases were identified as having a microdeletion at chromosome 5q35 detected by  
18 fluorescence in situ hybridization, whereas one SS case had no deletion of 5q35 but had

1 a *NSDI* mutation. *MLL2* mutations were detected in 2 of 3 KS cases.

## 2 4. Hypoglycemia

3 The onset time and blood insulin level during hypoglycemia, duration of IVG, maximum  
4 rate of GIR, introduction of diazoxide and estimated duration of hyperinsulinemia are  
5 presented in Tables III-VI. Twelve of the 16 BWS cases suffered from hypoglycemia as  
6 early as within 2 hr after birth, and the blood insulin level during hypoglycemia range  
7 from 2.8 - 49  $\mu$ IU/ml. All patients were treated with IVG at a maximum rate of 5.9 - 15  
8 mg/kg/min for 6 - 67 days. Six cases received medical treatment with diazoxide with a  
9 maximum dose of 3 - 18 mg/kg/day. Most cases recovered from HH within 1 month,  
10 however, one case (case 6) had persistent HH and was treated for three months.

11 As for SS, 7 of 9 patients presented with hypoglycemia within 3 hr after birth,  
12 and the blood insulin level during hypoglycemia ranged from 3.15 to 19.6  $\mu$ IU/ml. All  
13 cases were treated with IVG at a maximum rate of 4.6 - 11.0 mg/kg/min for 9 - 49 days.  
14 Two of 9 cases were treated with diazoxide at a maximum dose of 5-6 mg/kg/day. Most  
15 of the cases finished the IVG or diazoxide treatment within 3 weeks, although one case  
16 (case 7) required the treatments for two months. Regarding KS, only 3 cases were  
17 evaluated from the questionnaires. Two of three cases had hypoglycemia within 3 hr  
18 after birth. In one case (case 1), HH occurred 25 days after birth and was treated with

1 diazoxide. The median onset-times of HH after birth were 1 hr (immediately after birth -  
2 two days) for BWS, 1 hr (30 min - one day) for SS and 3 hr (30 min - 25 days) for KS.  
3 The rates of patients treated with diazoxide were 38% in BWS, 22% in SS, and 33% in  
4 KS, respectively. There were no apparent differences among the three syndromes  
5 regarding the glucose levels at HH.

6

## 7 DISCUSSION

8 Beckwith-Wiedemann syndrome (BWS) is a well-known congenital overgrowth  
9 syndrome associated with hyperinsulinemic hypoglycemia (HH) in the neonatal period  
10 [Munns and Batch, 2001; Weksberg et al., 2010]. Recent reports have demonstrated that  
11 infants with SS or KS also present with HH in infancy, although the detailed clinical  
12 characteristics of HH have not been well characterized [Genevieve et al., 2004; Matsuo  
13 et al., 2013; Subbarayan and Hussain, 2014]. One reason might be that characteristic  
14 features for SS and KS, such as facial anomaly or overgrowth, appeared gradually during  
15 their early childhood and then most of the patients were diagnosed by pediatric  
16 neurologists or dysmorphologists. Therefore, transient HH in neonatal period would not  
17 be essentially important for the diagnosis of SS or KS. We herein conducted the first  
18 nationwide survey in Japan to determine whether there were any characteristic



1 manifestations in patients with dysmorphic syndromes, BWS, SS or KS, who present HH  
2 in their neonatal period. On this purpose, we asked the neonatologists who cared for sick  
3 infants and followed them for a while. As a result, we found that severity of HH was  
4 clinically variable and no particular trend was observed in their neonatal period. When  
5 we compared the clinical or laboratory data, dysmorphic patients showed significantly  
6 larger body size, lower Apgar scores, higher insulin levels at HH and shorter durations of  
7 HH than non-dysmorphic infants with transient HH. It might be possible that normal to  
8 overweight status accompanied with asphyxia and severe but short-duration HH is a clue  
9 to diagnose underlying dysmorphic syndromes. Although we could not find specific  
10 clinical findings or biochemical data suggestive of SS or KS, particular symptoms such  
11 as accompanying major anomalies, feeding disability or developmental delay would  
12 suggest the diagnosis of these syndromes.

13       There are some limitations associated with this study. First, we did not recruit the  
14 patients by referral from pediatric neurologists or dysmorphologists; therefore, the total  
15 number of patients and characteristic features of the Japanese patients with these  
16 syndromes remained unclear from this study, and we did not evaluate the clinical  
17 differences between infants with HH and those without HH. Second, we performed this  
18 survey in institutions with NICUs; consequently, we might miss a small number of

1 patients who were treated outside the NICUs, such as in pediatric departments or  
2 obstetrics hospitals.

3

#### 4 CONCLUSIONS

5 Transient HH is an important complication occasionally observed in patients with SS  
6 and KS during the neonatal period. We propose that a careful observation for the signs  
7 of hypoglycemia and diagnosis of HH would be helpful for an early diagnosis of  
8 patients with BWS, SS and KS.

9

#### 10 ACKNOWLEDGMENTS

11 This study was supported by KAKEN # 15K08555 (awarded to N.T.) and #24591515  
12 (awarded to K.I) and by Novo Nordisk Growth Research Award 2013 (awarded to K.I).

#### 13 DISCLOSURE

14 The authors declare that they have no potential conflicts of interest associated with this  
15 study.

16

## REFERENCES

- 1
- 2
- 3
- 4
- 5 Arnoux JB, de Lonlay P, Ribeiro MJ, Hussain K, Blankenstein O, Mohnike K,  
6 Valayannopoulos V, Robert JJ, Rahier J, Sempoux C, Bellanne C, Verkarre V, Aigrain  
7 Y, Jaubert F, Brunelle F, Nihoul-Fekete C. 2010. Congenital hyperinsulinism. *Early*  
8 *Hum Dev* 86:287-294.
- 9 Arnoux JB, Verkarre V, Saint-Martin C, Montravers F, Brassier A, Valayannopoulos V,  
10 Brunelle F, Fournet JC, Robert JJ, Aigrain Y, Bellanne C, de Lonlay P. 2011.  
11 Congenital hyperinsulinism: current trends in diagnosis and therapy. *Orphanet J*  
12 *Rare Dis* 6:63.
- 13 Genevieve D, Amiel J, Viot G, Le Merrer M, Sanlaville D, Urtizberea A, Gerard M, Munnich  
14 A, Cormier-Daire V, Lyonnet S. 2004. Atypical findings in Kabuki syndrome: report  
15 of 8 patients in a series of 20 and review of the literature. *Am J Med Genet A* 129A:64-  
16 68.
- 17 Kapoor RR, James C, Hussain K. 2009. Hyperinsulinism in developmental syndromes.  
18 *Endocr Dev* 14:95-113.
- 19 Matsuo T, Ihara K, Ochiai M, Kinjo T, Yoshikawa Y, Kojima-Ishii K, Noda M, Mizumoto H,  
20 Misaki M, Minagawa K, Tominaga K, Hara T. 2013. Hyperinsulinemic hypoglycemia  
21 of infancy in Sotos syndrome. *Am J Med Genet A* 161A:34-37.
- 22 Mohamed Z, Arya VB, Hussain K. 2012. Hyperinsulinaemic hypoglycaemia: genetic  
23 mechanisms, diagnosis and management. *J Clin Res Pediatr Endocrinol* 4:169-181.
- 24 Munns CF, Batch JA. 2001. Hyperinsulinism and Beckwith-Wiedemann syndrome. *Arch Dis*  
25 *Child Fetal Neonatal Ed* 84:F67-69.
- 26 Subbarayan A, Hussain K. 2014. Hypoglycemia in Kabuki syndrome. *Am J Med Genet A*  
27 164A:467-471.
- 28 Weksberg R, Shuman C, Beckwith JB. 2010. Beckwith-Wiedemann syndrome. *Eur J Hum*  
29 *Genet* 18:8-14.
- 30 Yorifuji T. 2014. Congenital hyperinsulinism: current status and future perspectives. *Ann*  
31 *Pediatr Endocrinol Metab* 19:57-68.
- 32
- 33